Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies
Prospective studies should use standardized, spatially resolved, and longitudinal biomarker panels to enrich trials, distinguish prognostic from predictive effects, and adapt therapy when immune exclusion or antigen escape emerges, as well as define a practical framework for biomarker-guided immunotherapy.